Abstract 100P
Background
Rapid diagnostic services (RDS) are a two-week wait pathway for patients with non-specific symptoms (e.g., weight loss and fatigue), concerning of malignancy, that do not fulfil criteria for a site-specific cancer referral. Notoriously, patients without clear red flag symptoms have longer time to diagnosis and worse outcomes. RDS are being expanded across England to provide a new referral route for this cohort of patients to improve time to diagnosis and the patient journey. This study aimed to create a cancer risk stratification tool based on levels of standard serum biomarkers to help clinicians triage patients attending Guy’s RDC.
Methods
We analysed a panel of standard serum biomarkers assessed at referral for patients seen at Guy´s RDC between December 2016 and April 2022. Latent class analysis (LCA) was applied to investigate classes of individuals characterized based on their biomarker values (according to medical cut-offs), which were then examined as predictors of cancer using multivariate logistic regression. The abnormal biomarkers identified within LCA class with higher risk of cancer were used to create a scoring system, which was then developed into a cancer stratification tool.
Results
LCA identified four biomarker profiles: 1) normal values for all markers (51% of population); 2) abnormal values for haemoglobin, creatinine, and inflammatory markers (28%); 3) abnormal values for neutrophil to lymphocyte ratio, neutrophils, and inflammatory markers (12%); 4) abnormal values for multiple (n=10) markers (8%). Compared with class 1, class 4 had an increased risk of cancer (Odds ratio (OR) 6.33; 95% Confidence Interval (CI) 5.92-6.77). Based on the biomarkers identified in class 4 we created a score giving one point to each abnormal biomarker. A score of >=2 was associated with an increased risk of cancer (OR 3.09; 95%CI 2.91-3.27), as compared to a score of <2 (Area under the curve for test-training split: 0.68, C-index: 0.7).
Conclusions
Our innovative approach to triage patients with non-specific symptoms in the RDC for cancer diagnosis suggests that a combination of 10 standard biomarkers could be used to help facilitate a more efficient diagnosis of cancer when presenting with vague symptoms.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
104P - Hypomethylated immune gene promoters as potential biomarkers in oral and oropharyngeal cancer
Presenter: Petra Anić
Session: Cocktail & Poster Display session
Resources:
Abstract
105P - Implementation of technical improvements in cfMeDIP-Seq library preparation
Presenter: Martina Dameri
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Clinical application of next-generation sequencing in metastatic colorectal cancer (mCRC): Experience from a comprehensive cancer centre
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Unveiling mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) detection in cancer patients (pt) using a next-generation sequencing (NGS)-based molecular pre-screening program (MPP)
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
108P - Validation and implementation of a large NGS panel to test liquid biopsies from patients with suspected advanced non-small cell lung cancer (NSCLC) in an NHS genomic laboratory for the QuicDNA biomarker study
Presenter: Rachel Dodds
Session: Cocktail & Poster Display session
Resources:
Abstract
109P - A multiomic, single-cell measurable residual disease (scMRD) assay for phasing DNA mutations and surface immunophenotypes
Presenter: Simone Formisano
Session: Cocktail & Poster Display session
Resources:
Abstract
110P - Multicellular three-dimensional tumor spheroid of nasopharyngeal carcinoma
Presenter: Shiau Chuen Cheah
Session: Cocktail & Poster Display session
Resources:
Abstract
111P - Development of digital PCR for accurate measurement of HER2 amplification in 184 gastric cancer patients
Presenter: So Young Kang
Session: Cocktail & Poster Display session
Resources:
Abstract
112P - A novel methylation-sensitive assay for early detection of hepatocellular carcinoma to improve surveillance
Presenter: Jeong Sil Ha
Session: Cocktail & Poster Display session
Resources:
Abstract
113P - Evaluation of effects of tissue preservation methods on the proteome abundance through deep proteomics of breast cancer tissue
Presenter: Shashwati parihari
Session: Cocktail & Poster Display session
Resources:
Abstract